SEC Filings
Arteris Hits $25.8 Million In Revenue As Adjusted Operating Loss Shrinks To $1.2 Million
Royalties grew 71% over the trailing twelve months, while the chip-technology company forecasts $98.5 million to $99.5 million in annual sales.
SEC Filings
Royalties grew 71% over the trailing twelve months, while the chip-technology company forecasts $98.5 million to $99.5 million in annual sales.
SEC Filings
The biotech’s medicines remain in development, and its quarter-end balance is subject to completion of financial closing procedures.
SEC Filings
The quarterly loss widened to $18.5 million, while Rezolute plans approval applications for one or potentially both indications in 2027.
SEC Filings
Record output supported a higher annual forecast, while cash generation funded debt reduction and share repurchases.
SEC Filings
The higher outlook includes VitalConnect revenue, while litigation charges widened the quarterly loss.
SEC Filings
Research costs rose as the company prepares trial readouts and an FDA application, with cash expected to fund operations through 2029.
SEC Filings
Adjusted margins widened, but a change in how Franklin Templeton counts commitments complicates comparisons of investment flows.
SEC Filings
New pipeline expansions target Midwest power demand and Canadian LNG exports, while quarterly operating cash flow falls.
SEC Filings
Merchant advances expanded as Lightspeed reported a smaller loss and continued cost reductions under its three-year transformation.
SEC Filings
International attendance powered concert growth as Live Nation forecast nearly 180 million fans for 2026.
SEC Filings
Record quarterly sales and a $1.7 billion order backlog accompanied the higher outlook, while launch delays hurt space revenue.
SEC Filings
The chip-equipment supplier also approved a $0.33 quarterly dividend, payable January 6, 2027.